Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate

NCT03356444 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer
Castration-resistant Prostate Cancer
Drug

Interventions

DRUG: Abiraterone Acetate
DRUG: Docetaxel

Sponsor

West China Hospital